Discovery of 12-thiazole abietanes as selective inhibitors of the human metabolic serine hydrolase hABHD16A

Ahonen, Tiina J. and Savinainen, Juha R. and Yli-Kauhaluoma, Jari and Kalso, Eija and Laitinen, Jarmo T. and Moreira, Vânia M. (2018) Discovery of 12-thiazole abietanes as selective inhibitors of the human metabolic serine hydrolase hABHD16A. ACS Medicinal Chemistry Letters, 9 (12). pp. 1269-1273. ISSN 1948-5875

[thumbnail of Ahonen-etal-ACS-MCL-2018-Discovery-of-12-thiazole-abietanes-as-selective-inhibitors]
Preview
Text (Ahonen-etal-ACS-MCL-2018-Discovery-of-12-thiazole-abietanes-as-selective-inhibitors)
Ahonen_etal_ACS_MCL_2018_Discovery_of_12_thiazole_abietanes_as_selective_inhibitors.pdf
Accepted Author Manuscript

Download (344kB)| Preview

    Abstract

    Screening of an in-house library of compounds identified 12-thiazole abietanes as a new class of reversible inhibitors of the human metabolic serine hydrolase. Further optimization of the first hit compound lead to the 2-methylthiazole derivative 18, with an IC50 value of 3.4 ± 0.2 µM and promising selectivity. ABHD16A has been highlighted as a new target for in-flammation-mediated pain, although selective inhibitors of hABHD16A (human ABHD16A) have not yet been reported. Our study presents abietane-type diterpenoids as an attractive starting point for the design of selective ABHD16A inhibitors, which will contribute towards understanding the significance of hABHD16A inhibition in vivo.

    ORCID iDs

    Ahonen, Tiina J., Savinainen, Juha R., Yli-Kauhaluoma, Jari, Kalso, Eija, Laitinen, Jarmo T. and Moreira, Vânia M. ORCID logoORCID: https://orcid.org/0000-0001-6169-5035;